ArticleEClinicalMedicine2025
Maximum cold ischemia duration for a kidney allograft: a prediction model for allograft failure at the time of organ allocation.
Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Many determinants of kidney allograft failure are established at the time of allocation by organ distribution agencies. At this point, the main modifiable factor is the duration of cold ischemia (CIT). Currently, no practical tool exists to determine the maximum permissible cold ischemia time for a specific recipient at allocation. Methods: We analyzed two prospective cohorts of kidney transplant recipients from European centers: a derivation cohort of 7040 patients from 10 centers (Barcelona; Leuven; Oslo; Paris Necker, Lyon, Nantes, Nancy, Montpellier, Nice, Paris Saint Louis) with data collected between 2005 and 2020, and a validation cohort of 6131 patients from 6 French centers (Paris Necker, Lyon, Nantes, Nancy, Montpellier, Nice) with data collected between 2008 and 2019. The main outcome was allograft failure (return to dialysis or pre-emptive retransplantation). We assessed 26 determinants of allograft failure available at the time of allograft allocation including cold ischemia time as a modifiable factor. Prediction models were developed using a classical survival analysis and a competing risk framework. Findings: Allograft failure occurred in 16% (1113) of the derivation cohort and 14% (832) of the validation cohort. Independent determinants of allograft failure were donor age (HR 2.2 [1.9-2.6] for donors above 65 years old), previous allografts (HR 1.5 [1.3-1.6]), dialysis history (HR 1.7 [1.3-2] for Hemodialysis), diabetes (HR 1.4 [1.2-1.6]), vascular disease (HR 1.3 [1.1-1.5]), HLA-DR incompatibility (HR 1.2 [1.1-1.3]), donor serum creatinine (HR 1 [1-1]), and cold ischemia time (HR 1 [1-1]). Donor age was the strongest contributor, while cold ischemia was the only modifiable factor. These factors were combined into two predictive models of kidney allograft failure (Cox regression and Fine Gray) showing accurate calibration, and discrimination with a C-Index of 0.66 (95% CI: 0.63-0.70 at year one) on the validation cohort for the Fine Gray model. The Fine-Gray model, which accounts for the competing risks between allograft failure and patient death, was used to develop a practical tool for predicting allograft failure based on cold ischemia. Interpretation: Prediction model at the time of allocation provides a simple and practical tool which may guide organ distribution agencies and medico-surgical teams by customizing cold ischemia time for a kidney allograft transplantation. Funding: Centaure Foundation (SIREN 499,947,398-http://www.fondation-centaure.org) none of the funding sources had any role in study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.